Ranbaxy Halts Production Of Generic Lipitor

Law360, New York (November 30, 2012, 10:43 PM EST) -- India-based drugmaker Ranbaxy Laboratories Ltd. has halted production of its generic version of cholesterol treatment Lipitor after recalling several dozen batches over concerns that the pills might contain tiny glass fragments, the U.S. Food and Drug Administration said Thursday.

Ranbaxy decided to stop production of the drug, one of the most popular medications in the U.S., until it had thoroughly investigated the cause of the glass particulates and fixed the problem, the FDA said.

Ranbaxy said that the recall, which began Nov. 9, should be viewed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.